197 related articles for article (PubMed ID: 25114135)
1. A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole.
Sperandio da Silva GM; Mediano MF; Alvarenga Americano do Brasil PE; da Costa Chambela M; da Silva JA; de Sousa AS; Xavier SS; Rodrigues da Costa A; Magalhães Saraiva R; Hasslocher-Moreno AM
Antimicrob Agents Chemother; 2014 Nov; 58(11):6371-7. PubMed ID: 25114135
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic Profile and Adverse Drug Reactions in a Prospective Therapeutic Cohort of Chagas Disease Patients Treated with Benznidazole.
Franco LAM; Moreira CHV; Buss LF; Oliveira LC; Martins RCR; Manuli ER; Lindoso JAL; Busch MP; Pereira AC; Sabino EC
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669428
[TBL] [Abstract][Full Text] [Related]
3. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease.
Olivera MJ; Cucunubá ZM; Valencia-Hernández CA; Herazo R; Agreda-Rudenko D; Flórez C; Duque S; Nicholls RS
PLoS One; 2017; 12(9):e0185033. PubMed ID: 28949997
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres.
Crespillo-Andújar C; López-Vélez R; Trigo E; Norman F; Díaz-Menéndez M; Monge-Maillo B; Arsuaga M; Pérez-Molina JA
Clin Microbiol Infect; 2020 Mar; 26(3):384.e1-384.e4. PubMed ID: 31740423
[TBL] [Abstract][Full Text] [Related]
6. Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil.
Gontijo MKCL; Arruda HMBDS; Noronha EF; Toledo MI
Rev Soc Bras Med Trop; 2020; 53():e20190150. PubMed ID: 31994658
[TBL] [Abstract][Full Text] [Related]
7. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease.
Pinazo MJ; Guerrero L; Posada E; Rodríguez E; Soy D; Gascon J
Antimicrob Agents Chemother; 2013 Jan; 57(1):390-5. PubMed ID: 23114763
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pharmacological profile of benznidazole for treatment of Chagas disease.
Kratz JM; Garcia Bournissen F; Forsyth CJ; Sosa-Estani S
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):943-957. PubMed ID: 30111183
[TBL] [Abstract][Full Text] [Related]
9. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease.
Sperandio da Silva GM; Mediano MFF; Hasslocher-Moreno AM; Holanda MT; Silvestre de Sousa A; Sangenis LHC; Brasil PEAAD; Mejía RA; Fux CP; Cubides JC; Saraiva RM; Brum-Soares LM
J Antimicrob Chemother; 2017 Sep; 72(9):2596-2601. PubMed ID: 28645201
[TBL] [Abstract][Full Text] [Related]
10. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
[TBL] [Abstract][Full Text] [Related]
11. Drug Repurposing in Chagas Disease: Chloroquine Potentiates Benznidazole Activity against Trypanosoma cruzi
Pandey RP; Nascimento MS; Franco CH; Bortoluci K; Silva MN; Zingales B; Gibaldi D; Castaño Barrios L; Lannes-Vieira J; Cariste LM; Vasconcelos JR; Moraes CB; Freitas-Junior LH; Kalil J; Alcântara L; Cunha-Neto E
Antimicrob Agents Chemother; 2022 Nov; 66(11):e0028422. PubMed ID: 36314800
[TBL] [Abstract][Full Text] [Related]
12. Clomipramine and benznidazole association for the treatment of acute experimental Trypanosoma cruzi infection.
Strauss M; Lo Presti MS; Bazán PC; Baez A; Fauro R; Esteves B; Sanchez Negrete O; Cremonezzi D; Paglini-Oliva PA; Rivarola HW
Parasitol Int; 2013 Jun; 62(3):293-9. PubMed ID: 23500720
[TBL] [Abstract][Full Text] [Related]
13. Adverse events after the use of benznidazole in infants and children with Chagas disease.
Altcheh J; Moscatelli G; Moroni S; Garcia-Bournissen F; Freilij H
Pediatrics; 2011 Jan; 127(1):e212-8. PubMed ID: 21173000
[TBL] [Abstract][Full Text] [Related]
14. Tolerance of benznidazole in a United States Chagas Disease clinic.
Miller DA; Hernandez S; Rodriguez De Armas L; Eells SJ; Traina MM; Miller LG; Meymandi SK
Clin Infect Dis; 2015 Apr; 60(8):1237-40. PubMed ID: 25601454
[TBL] [Abstract][Full Text] [Related]
15. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.
Yun O; Lima MA; Ellman T; Chambi W; Castillo S; Flevaud L; Roddy P; Parreño F; Albajar Viñas P; Palma PP
PLoS Negl Trop Dis; 2009 Jul; 3(7):e488. PubMed ID: 19582142
[TBL] [Abstract][Full Text] [Related]
16. High frequency of adverse reactions and discontinuation with benznidazole treatment for chronic Chagas disease in Milan, Italy.
Antinori S; Grande R; Bianco R; Traversi L; Cogliati C; Torzillo D; Repetto E; Corbellino M; Milazzo L; Galli M; Galimberti L
Clin Infect Dis; 2015 Jun; 60(12):1873-5. PubMed ID: 25805302
[No Abstract] [Full Text] [Related]
17. Short-course Benznidazole treatment to reduce Trypanosoma cruzi parasitic load in women of reproductive age (BETTY): a non-inferiority randomized controlled trial study protocol.
Cafferata ML; Toscani MA; Althabe F; Belizán JM; Bergel E; Berrueta M; Capparelli EV; Ciganda Á; Danesi E; Dumonteil E; Gibbons L; Gulayin PE; Herrera C; Momper JD; Rossi S; Shaffer JG; Schijman AG; Sosa-Estani S; Stella CB; Klein K; Buekens P
Reprod Health; 2020 Aug; 17(1):128. PubMed ID: 32831069
[TBL] [Abstract][Full Text] [Related]
18. Arthritis and benznidazole: more closely related than we thought.
Aldasoro E; Pinazo MJ; Oliveira I; Munoz J; Posada E; Requena-Méndez A; Serret N; Gascon J
Antimicrob Agents Chemother; 2015 Jan; 59(1):727-9. PubMed ID: 25385100
[TBL] [Abstract][Full Text] [Related]
19. Adverse systemic reaction to benznidazole.
Coronel MV; Frutos LO; Muñoz EC; Valle DK; Rojas DH
Rev Soc Bras Med Trop; 2017; 50(1):145-147. PubMed ID: 28327820
[TBL] [Abstract][Full Text] [Related]
20. Tolerance of benznidazole in treatment of Chagas' disease in adults.
Pinazo MJ; Muñoz J; Posada E; López-Chejade P; Gállego M; Ayala E; del Cacho E; Soy D; Gascon J
Antimicrob Agents Chemother; 2010 Nov; 54(11):4896-9. PubMed ID: 20823286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
